The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1563
ISSUE 1563
January 14, 2019
Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
January 14, 2019 (Issue: 1563)
Tildrakizumab-asmn (Ilumya – Sun), an interleukin
(IL)-23 antagonist, has been approved by the FDA for
treatment of adults with moderate to severe plaque
psoriasis who are candidates for systemic therapy or
phototherapy. Tildrakizumab is the second selective
IL-23 antagonist to be approved for this indication;
guselkumab (Tremfya) was the first.
... more
- Guselkumab (Tremfya) for psoriasis. Med Lett Drugs Ther 2017; 59:179.
- J Bilal et al. A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis. J Dermatolog Treat 2018; 29:569.
- Drugs for psoriasis. Med Lett Drugs Ther 2015; 57:81.
- E Sbidian et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2017; 12:CD011535.
- D Fiorentino et al. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol 2017; 77:845.
- RE Kalb et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol 2015; 151:961.
- HJ Kim and MG Lebwohl. Biologics and psoriasis: the beat goes on. Dermatol Clin 2019; 37:29.
- C Bangert and T Kopp. Tildrakizumab for the treatment of psoriasis. Immunotherapy 2018; 10:1105.
- K Reich et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet 2017; 390:276.
- B Elewski et al. Sustained and improved efficacy of tildrakizumab from week 28 to week 52 in treating moderate-to-severe plaque psoriasis. SKIN The Journal of Cutaneous Medicine 2018; Abstract 112: Poster 47. Available at: https://jofskin.org. Accessed December 20, 2018.
- K Papp et al. Clinical efficacy of tildrakizumab in patients with chronic plaque psoriasis over 2 years of treatment: results from long-term extensions to 2 phase 3 clinical studies. Poster. Presented at the 13th Winter Dermatology Conference, January 12-17, 2018. Maui, HI.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Tildrakizumab (Ilumya) - Another IL-23 Antagonist for Psoriasis
Article code: 1563b
Electronic, downloadable article - $45
Article code: 1563b
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian